SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback